Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sat · 31 Oct 2026
Standard addition

Real-World Treatment Patterns and Outcomes of Zanubrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma at University of California Academic Health Centers: A Retrospective Cohort Study.

Zanubrutinib kept patients on treatment longer than acalabrutinib in real-world blood cancer care, with similar survival outcomes between the two drugs.

This retrospective cohort study examined real-world outcomes with zanubrutinib versus acalabrutinib. Zanubrutinib was associated with longer treatment persistence, while time to next treatment and overall survival did not differ significantly.

What the study was

Study design
Retrospective cohort study
Population
481 adults with chronic lymphocytic leukemia or small lymphocytic lymphoma
Sample size
481
Category
Treatment Innovation
Maturity
Validated
Journal
Oncology and therapy

Why it surfaced

Retained as a standard-priority retrospective cohort study after PubMed abstract review; the score reflects clinical relevance, design strength, novelty, and population need under the v1.3 conservative rubric.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.